Phase III randomized controlled clinical trials [34–36] and meta-analyses [37] focused on this pathway have confirmed that blocking the binding between PD-L1 and PD-1 using immune checkpoint inhibitors restores T cells’ ability to recognize and eliminate tumor cells. This evidence concerns the gene PDCD1 and neoplasm.